

TreeFrog Therapeutics and QC-Stem, the International Consortium on iPS cell quality, awarded by Galien Foundation

TreeFrog Therapeutics (Bordeaux, France), a biotechnology startup, received the prestigious GALIEN MEDSTARTUP award at a virtual awards ceremony held in Boston on October 26, 2020. The company has been developing high-throughput culture technologies and quality testing systems to provide iPS-derived cells for medical purposes in a safe and affordable manner. The company's partnership with QC-Stem*, an international consortium for the quality evaluation of iPS-derived cells, was highly evaluated, and it was awarded in the "BEST COLLABORATOIN IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY" category. The company is talking on a research collaboration with the Research and Development Center for Cell Therapy, through matching by Center for Cluster Development and Coordination. The award will be a tailwind for future research.

Fore more details (TreeFrog Website):

<https://treefrog.fr/treefrog-therapeutics-awarded-prix-galien-medstartup-international-consortium-ips-quality/>

* Bringing together experts from the FBRI in Kobe, Japan, the Harvard Stem Cell Institute and the Dana-Farber Cancer Institute in Boston, USA and the Imagine Institute in Paris, France, this international consortium aims to assess the quality of pluripotent stem cells produced with TreeFrog Therapeutics' proprietary C-Stem™ technology.

● TreeFrog Therapeutics

<https://treefrog.fr/>

● Prix Galien MedStartup Prize (PDF)

https://www.fbri-kobe.org/pdf/Prix_Galien_Medstartup2020.pdf

● Research and Development Center for Cell Therapy

<https://www.fbri-kobe.org/english/rdc/>

● Center for Cluster Development and Coordination

<https://www.fbri-kobe.org/english/cluster/>